Clinical Trial: Intrauterine Balloon (Bakri(c)) Versus Uterine Tamponade With Chitosan Gauze (Celox PPH(c)) in the Management of Postpartum Hemorrhage Refractory to Medical Treatmen

U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06996808) titled 'Intrauterine Balloon (Bakri(c)) Versus Uterine Tamponade With Chitosan Gauze (Celox PPH(c)) in the Management of Postpartum Hemorrhage Refractory to Medical Treatmen' on May 12.

Brief Summary: Postpartum hemorrhage (PPH) remains one of the leading causes of maternal morbidity and mortality worldwide, particularly in low- and middle-income countries. It is defined as blood loss of more than 500 mL after vaginal delivery or more than 1000 mL after cesarean section, but severe PPH is typically identified when blood loss exceeds 1000 mL regardless of delivery mode. The initial management of PPH includes the administration of uterotonics ...